Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY – Get Free Report) shares shot up 5.6% during mid-day trading on Tuesday . The company traded as high as $6.60 and last traded at $6.55. 2,561 shares changed hands during trading, an increase of 26% from the average session volume of 2,030 shares. The stock had previously closed at $6.20.
Clinuvel Pharmaceuticals Trading Up 5.6%
The business’s 50-day simple moving average is $7.00 and its 200-day simple moving average is $7.25.
Clinuvel Pharmaceuticals Company Profile
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Featured Articles
- Five stocks we like better than Clinuvel Pharmaceuticals
- Should You Invest in Penny Stocks?
- 3 Hot Trades for Insiders, But Are They Good Buys for Investors?
- 5 discounted opportunities for dividend growth investors
- Why Qualcomm’s Latest Price Target Can’t Be Ignored
- Dividend Payout Ratio Calculator
- Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
